cannabidiol

Description: NOT AVAILABLE (CONTROLLED SUBSTANCE; Schedule I drugs under the Controlled Substances Act.). Cannabidiol (CBD; trade name: Epidiolex) is a phytocannabinoid discovered in 1940 and initially thought not to be psychoactive. It is one of at least 113 cannabinoids identified in hemp plants, accounting for up to 40% of the plant's extract. Articles published in 2017 and 2018 incorporating numerous clinical trials concluded that cannabidiol is an effective treatment for certain types of childhood epilepsy. An orally administered cannabidiol solution (brand name: Epidiolex) was approved by the US FDA on June 25th of 2018 as a treatment for two rare forms of childhood epilepsy, Lennox-Gastaut syndrome and Dravet syndrome.

References: Neurol. Neurosurg. Psychiatry. 89 (7): 741–753; J Epilepsy Res. 7 (2): 61–76.